Cancer Genetics and Epigenetics 2024, Vol.12, No.2, 79-87 http://medscipublisher.com/index.php/cge 87 Samsom K., Schipper L., Roepman P., Bosch L., Lalezari F., Klompenhouwer E., Langen A., Buffart T., Riethorst I., Schoenmaker L., Schout D., Noort V., Berg J., Bruijn E., Hoeven J., Snellenberg H., Kolk L., Cuppen E., Voest E., Meijer G., and Monkhorst K., 2022, Feasibility of whole‐genome sequencing‐ based tumor diagnostics in routine pathology practice, The Journal of Pathology, 258: 179-188. https://doi.org/10.1002/path.5988 Schaid D., McDonnell S., FitzGerald L., DeRycke L., Fogarty Z., Giles G., MacInnis R., Southey M., Nguyen-Dumont T., Cancel-Tassin G., Cussenot O., Whittemore A., Sieh W., Ioannidis N., Hsieh C., Stanford J., Schleutker J., Cropp C., Carpten J., Hoegel J., Eeles R., Kote-Jarai Z., Ackerman M., Klein C., Mandal D., Cooney K., Bailey-Wilson J., Helfand B., Catalona W., Wiklund F., Riska S., Bahetti S., Larson M., Albright L., Teerlink C., Xu J., Isaacs W., Ostrander E., and Thibodeau S., 2020, Two-stage study of familial prostate cancer by whole-exome sequencing and custom capture identifies 10 novel genes associated with the risk of prostate cancer, European Urology, 79(3): 353-361. https://doi.org/10.1016/j.eururo.2020.07.038 Sumanasuriya S., Seed G., Parr H., Christova R., Pope L., Bertan C., Bianchini D., Rescigno P., Figueiredo I., Goodall J., Fowler G., Flohr P., Mehra N., Neeb A., Rekowski J., Eisenberger M., Sartor O., Oudard S., Geffriaud-Ricouard C., Ozatilgan A., Chadjaa M., Macé S., Lord C., Baxter J., Pettitt S., Lambros M., Sharp A., Mateo J., Carreira S., Yuan W., and Bono J., 2021, Elucidating prostate cancer behaviour during treatment via low-pass whole-genome sequencing of circulating tumour DNA, European Urology, 80: 243-253. https://doi.org/10.1016/j.eururo.2021.05.030 Wedge D., Gundem G., Mitchell T., Woodcock D., Martincorena I., Ghori M., Zamora J., Butler A., Whitaker H., Kote-Jarai Z., Alexandrov L., Loo P., Massie C., Dentro S., Warren A., Verrill C., Berney D., Dennis N., Merson S., Hawkins S., Howat W., Lu Y., Lambert A., Kay J., Kremeyer B., Karászi K., Luxton H., Camacho N., Marsden L., Edwards S., Matthews L., Bo V., Leongamornlert D., Mclaren S., Ng A., Yu Y., Zhang H., Dadaev T., Thomas S., Easton D., Ahmed M., Bancroft E., Fisher C., Livni N., Nicol D., Tavaré S., Gill P., Greenman C., Khoo V., As N., Kumar P., Ogden C., Cahill D., Thompson A., Mayer E., Rowe E., Dudderidge T., Gnanapragasam V., Shah N., Raine K., Jones D., Menzies A., Stebbings L., Teague J., Hazell S., Corbishley C., Bono J., Attard G., Isaacs W., Visakorpi T., Fraser M., Boutros P., Bristow R., Workman P., Sander C., Hamdy F., Futreal A., McDermott U., Al-Lazikani B., Lynch A., Bova G., Foster C., Brewer D., Neal D., Cooper C., Eeles R., Group C., and Consortium T., 2018, Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets, Nature Genetics, 50: 682-692. https://doi.org/10.1038/s41588-018-0086-z Weiss S., Lamy P., Nørgaard M., Knudsen M., Jensen J., Pedersen J., Borre M., and Sørensen K., 2022, Abstract 3409: whole genome sequencing of liquid tumor biopsies (ctDNA) from men with metastatic castration resistant prostate cancer, Cancer Research, 82(12_Supplement): 3409-3409. https://doi.org/10.1158/1538-7445.am2022-3409
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==